Premium
Essentials from the 2015 European AIDS Clinical Society ( EACS ) guidelines for the treatment of adult HIV ‐positive persons
Author(s) -
Ryom L,
Boesecke C,
Gisler V,
Manzardo C,
Rockstroh JK,
Puoti M,
Furrer H,
Miro JM,
Gatell JM,
Pozniak A,
Behrens G,
Battegay M,
Lundgren JD
Publication year - 2016
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12322
Subject(s) - medicine , expanded access , guideline , dolutegravir , coinfection , hepatitis c , intensive care medicine , adverse effect , human immunodeficiency virus (hiv) , viral load , immunology , antiretroviral therapy , pathology
Background The European AIDS Clinical Society ( EACS ) guidelines are intended for all clinicians involved in the care of HIV ‐positive persons, and are available in print, online, and as a free App for download for iP hone and Android. Guideline highlights The 2015 version of the EACS guidelines contains major revisions in all sections; antiretroviral treatment ( ART ), comorbidities, coinfections and opportunistic diseases. Among the key revisions is the recommendation of ART for all HIV ‐positive persons, irrespectively of CD 4 count, based on the Strategic Timing of AntiRetroviral Treatment ( START ) study results. The recommendations for the preferred and the alternative ART options have also been revised, and a new section on the use of pre‐exposure prophylaxis (Pr EP ) has been added. A number of new antiretroviral drugs/drug combinations have been added to the updated tables on drug−drug interactions, adverse drug effects, dose adjustment for renal/liver insufficiency and for ART administration in persons with swallowing difficulties. The revisions of the coinfection section reflect the major advances in anti‐hepatitis C virus ( HCV ) treatment with direct‐acting antivirals with earlier start of treatment in individuals at increased risk of liver disease progression, and a phasing out of interferon‐containing treatment regimens. The section on opportunistic diseases has been restructured according to individual pathogens/diseases and a new overview table has been added on CD 4 count thresholds for different primary prophylaxes. Conclusions The diagnosis and management of HIV infection and related coinfections, opportunistic diseases and comorbidities continue to require a multidisciplinary effort for which the 2015 version of the EACS guidelines provides an easily accessable and updated overview.